Literature DB >> 7695249

Evidence of alkaline phosphatase interference in a zidovudine radioimmunoassay.

A M O'Donnell1, D J Letting, M F DeRemer, G D Morse.   

Abstract

Phosphorylated zidovudine (ZDV) concentrations may provide a link between drug exposure and clinical efficacy since these would include the active, intracellular form of the drug, ZDV triphosphate. Many groups are investigating the optimal methodology that can be used to accomplish this goal. The initial purpose of the present studies was to examine the effect of the inclusion of cell wash steps on the quantitation of intracellular ZDV. Ten milliliters of whole blood collected from healthy volunteers was spiked with increasing ZDV concentrations (0.187, 0.375, 1.87, and 3.75 microM), allowed to equilibrate at room temperature for 1 h, and separated into whole-blood components by a density gradient procedure. A mononuclear cell pellet was obtained, reconstituted with 2 ml of phosphate-buffered saline (PBS), and split into two aliquots, one of which was not washed at all and the other of which was washed four times with 1 ml of PBS. All samples were analyzed by ZDV radioimmunoassay (RIA) after a 1:1 dilution with either 1 mg of alkaline phosphatase (type 1-S; Sigma) per ml or PBS. Parent ZDV was measured in those samples which were not treated with the enzyme, while total ZDV was measured in those samples which were exposed to alkaline phosphatase (21 degrees C for 1 h). The result of the difference between the two samples is total phosphorylated ZDV. During the experiment, evidence of alkaline phosphatase interference with the RIA became apparent, confusing interpretation of intracellular ZDV concentrations. This evidence was based on three sets of data. First, wash samples showed increases in ZDV concentrations of as great as 0.127 microgramM after exposure to alkaline phosphatase, even though on microscopic inspection the wash samples were acellular. Second, the sum of total ZDV recovered from the four wash samples plus the washed cell pellet was as much as 14-fold greater than the total ZDV measured in the unwashed cell pellet. Theoretically, at least, these two entities should be equal. Finally, control samples of alkaline phosphatase in PBS (0.5 mg/ml) run directly through the assay measured false ZDV levels ranging from 0.002 to 0.075 microgramM (0.6 to 20 ng/ml). Alkaline phosphatase is frequently used to measure phosphorylated anabolites of ZDV in peripheral blood mononuclear cells. These data show that the particular form of alkaline phosphatase used may interfere with the ZDV RIA and may confuse the interpretation of phosphorylated anabolite concentrations of ZDV.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7695249      PMCID: PMC188271          DOI: 10.1128/AAC.38.12.2689

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  17 in total

1.  Pharmacokinetics of zidovudine phosphorylation in patients infected with the human immunodeficiency virus.

Authors:  B N Stretcher; A J Pesce; P E Hurtubise; P T Frame
Journal:  Ther Drug Monit       Date:  1992-08       Impact factor: 3.681

2.  Preliminary analysis of the Concorde trial. Concorde Coordinating Committee.

Authors:  J P Aboulker; A M Swart
Journal:  Lancet       Date:  1993-04-03       Impact factor: 79.321

3.  Concentrations of phosphorylated zidovudine (ZDV) in patient leukocytes do not correlate with ZDV dose or plasma concentrations.

Authors:  B N Stretcher; A J Pesce; J A Murray; P E Hurtubise; W H Vine; P T Frame
Journal:  Ther Drug Monit       Date:  1991-07       Impact factor: 3.681

4.  In vitro measurement of phosphorylated zidovudine in peripheral blood leucocytes.

Authors:  B N Stretcher; A J Pesce; J R Wermeling; P E Hurtubise
Journal:  Ther Drug Monit       Date:  1990-09       Impact factor: 3.681

5.  A controlled trial of early versus late treatment with zidovudine in symptomatic human immunodeficiency virus infection. Results of the Veterans Affairs Cooperative Study.

Authors:  J D Hamilton; P M Hartigan; M S Simberkoff; P L Day; G R Diamond; G M Dickinson; G L Drusano; M J Egorin; W L George; F M Gordin
Journal:  N Engl J Med       Date:  1992-02-13       Impact factor: 91.245

6.  A method for the quantification of intracellular zidovudine nucleotides.

Authors:  H Kuster; M Vogt; B Joos; V Nadai; R Lüthy
Journal:  J Infect Dis       Date:  1991-10       Impact factor: 5.226

7.  The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial.

Authors:  M A Fischl; D D Richman; M H Grieco; M S Gottlieb; P A Volberding; O L Laskin; J M Leedom; J E Groopman; D Mildvan; R T Schooley
Journal:  N Engl J Med       Date:  1987-07-23       Impact factor: 91.245

8.  Intracellular zidovudine (ZDV) and ZDV phosphates as measured by a validated combined high-pressure liquid chromatography-radioimmunoassay procedure.

Authors:  J T Slusher; S K Kuwahara; F M Hamzeh; L D Lewis; D M Kornhauser; P S Lietman
Journal:  Antimicrob Agents Chemother       Date:  1992-11       Impact factor: 5.191

9.  Phosphorylation of 3'-azido-3'-deoxythymidine and selective interaction of the 5'-triphosphate with human immunodeficiency virus reverse transcriptase.

Authors:  P A Furman; J A Fyfe; M H St Clair; K Weinhold; J L Rideout; G A Freeman; S N Lehrman; D P Bolognesi; S Broder; H Mitsuya
Journal:  Proc Natl Acad Sci U S A       Date:  1986-11       Impact factor: 11.205

10.  Inhibition of replication and cytopathic effect of human T cell lymphotropic virus type III/lymphadenopathy-associated virus by 3'-azido-3'-deoxythymidine in vitro.

Authors:  H Nakashima; T Matsui; S Harada; N Kobayashi; A Matsuda; T Ueda; N Yamamoto
Journal:  Antimicrob Agents Chemother       Date:  1986-12       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.